Jazz Pharmaceuticals PLC
General ticker "JAZZ" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $7.5B
Jazz Pharmaceuticals PLC follows the US Stock Market performance with the rate: 0.5%.
Estimated limits based on current volatility of 1.5%: low 121.38$, high 125.17$
Factors to consider:
- US accounted for 91.0% of revenue in the fiscal year ended 2023-12-31
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [85.31$, 144.03$]
- 2024-12-30 to 2025-12-30 estimated range: [86.23$, 144.51$]
Financial Metrics affecting the JAZZ estimates:
- Positive: Non-GAAP EPS, $ of 18.32 > 2.29
- Positive: Operating cash flow per share per price, % of 14.33 > 12.76
- Positive: 9.05 < Operating profit margin, % of 15.09
- Negative: Industry earnings per price (median), % of -15.01 <= 1.31
- Positive: Inventory ratio change, % of -3.54 <= -1.03
- Positive: 2.86 < Return on assets ratio (scaled to [-100,100]) of 3.51
Short-term JAZZ quotes
Long-term JAZZ plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $3,094.24MM | $3,659.37MM | $3,834.20MM |
| Operating Expenses | $2,923.96MM | $3,724.90MM | $3,255.62MM |
| Operating Income | $170.28MM | $-65.53MM | $578.58MM |
| Non-Operating Income | $-283.12MM | $-307.26MM | $-280.65MM |
| Interest Expense | $278.77MM | $288.24MM | $289.44MM |
| R&D Expense | $505.75MM | $590.45MM | $849.66MM |
| Income(Loss) | $-112.84MM | $-372.78MM | $297.93MM |
| Taxes | $216.12MM | $-158.65MM | $-119.91MM |
| Other Income(Loss) | $-0.71MM | $-9.92MM | $-3.01MM |
| Profit(Loss) | $-329.67MM | $-224.06MM | $414.83MM |
| Stockholders Equity | $3,965.19MM | $3,085.73MM | $3,737.00MM |
| Inventory | $1,072.72MM | $714.06MM | $597.04MM |
| Assets | $12,298.64MM | $10,835.25MM | $11,393.36MM |
| Operating Cash Flow | $778.51MM | $1,271.98MM | $1,092.01MM |
| Capital expenditure | $45.53MM | $498.19MM | $23.96MM |
| Investing Cash Flow | $-5,212.14MM | $-446.23MM | $-163.06MM |
| Financing Cash Flow | $3,970.52MM | $-529.49MM | $-305.25MM |
| Earnings Per Share* | $-5.51 | $-3.42 | $6.95 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.